Show simple item record

dc.contributor.authorPaisley, Angela N
dc.contributor.authorRoberts, Margaret E
dc.contributor.authorTrainer, Peter J
dc.date.accessioned2009-06-09T16:31:26Z
dc.date.available2009-06-09T16:31:26Z
dc.date.issued2007-05
dc.identifier.citationWithdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. 2007, 66 (5):723-6 Clin. Endocrinol.en
dc.identifier.issn0300-0664
dc.identifier.pmid17388793
dc.identifier.doi10.1111/j.1365-2265.2007.02811.x
dc.identifier.urihttp://hdl.handle.net/10541/70036
dc.description.abstractBACKGROUND: The prevalence of gallstones (GS) is increased in acromegaly and further increased by somatostatin analogue (SA) therapy. The incidence is reported at 10-63%, but they are often asymptomatic and rarely require definitive management. Evidence suggests discontinuation of SA may precipitate acute biliary problems. OBJECTIVE: To determine the frequency of symptomatic gallstones in patients treated with SA. DESIGN: Retrospective analysis of prospectively followed patients in our centre. RESULTS: Fifty patients (30 male, mean age 54 +/- 16 years) were on treatment with SA on 1 January 2003. Fifteen (11 male, mean age 50 +/- 17 years) have since discontinued SA with three proceeding to develop acute cholecystitis and two, biliary colic necessitating cholecystectomy. Three of the five had abnormal liver enzymes at or within 3 months of symptomatic presentation. Two of the remaining 35 patients experienced biliary colic necessitating cholecystectomy. These data indicate a highly significant increase in acute biliary problems on discontinuing SA (5 in 27.67 patient 'off-treatment' years vs. 2 in 299 patient treatment years, chi(2), P < 0.0001). All seven patients experiencing problems were male (P = 0.01). CONCLUSION: This analysis demonstrates the high incidence of symptomatic GS following SA withdrawal, particularly in men. Although liver enzymes were raised no common abnormality was evident to aid as a predictor of future symptoms. We recommend all patients due to stop SA be forewarned of the risk of acute biliary problems. Further work is required to confirm if there is a gender-related difference in the incidence of acute biliary problems on discontinuing SA therapy.
dc.language.isoenen
dc.subject.meshAcromegaly
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshChi-Square Distribution
dc.subject.meshFemale
dc.subject.meshGallstones
dc.subject.meshHuman Growth Hormone
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOctreotide
dc.subject.meshPeptides, Cyclic
dc.subject.meshReceptors, Somatotropin
dc.subject.meshRetrospective Studies
dc.subject.meshRisk
dc.subject.meshSomatostatin
dc.subject.meshWithholding Treatment
dc.titleWithdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Wilmslow Road, Withington, Manchester, M20 4BX.en
dc.identifier.journalClinical Endocrinologyen
html.description.abstractBACKGROUND: The prevalence of gallstones (GS) is increased in acromegaly and further increased by somatostatin analogue (SA) therapy. The incidence is reported at 10-63%, but they are often asymptomatic and rarely require definitive management. Evidence suggests discontinuation of SA may precipitate acute biliary problems. OBJECTIVE: To determine the frequency of symptomatic gallstones in patients treated with SA. DESIGN: Retrospective analysis of prospectively followed patients in our centre. RESULTS: Fifty patients (30 male, mean age 54 +/- 16 years) were on treatment with SA on 1 January 2003. Fifteen (11 male, mean age 50 +/- 17 years) have since discontinued SA with three proceeding to develop acute cholecystitis and two, biliary colic necessitating cholecystectomy. Three of the five had abnormal liver enzymes at or within 3 months of symptomatic presentation. Two of the remaining 35 patients experienced biliary colic necessitating cholecystectomy. These data indicate a highly significant increase in acute biliary problems on discontinuing SA (5 in 27.67 patient 'off-treatment' years vs. 2 in 299 patient treatment years, chi(2), P < 0.0001). All seven patients experiencing problems were male (P = 0.01). CONCLUSION: This analysis demonstrates the high incidence of symptomatic GS following SA withdrawal, particularly in men. Although liver enzymes were raised no common abnormality was evident to aid as a predictor of future symptoms. We recommend all patients due to stop SA be forewarned of the risk of acute biliary problems. Further work is required to confirm if there is a gender-related difference in the incidence of acute biliary problems on discontinuing SA therapy.


This item appears in the following Collection(s)

Show simple item record